High Dimensional Variable Selection with Error Control.
Repository Usage Stats
Background. The iterative sure independence screening (ISIS) is a popular method in selecting important variables while maintaining most of the informative variables relevant to the outcome in high throughput data. However, it not only is computationally intensive but also may cause high false discovery rate (FDR). We propose to use the FDR as a screening method to reduce the high dimension to a lower dimension as well as controlling the FDR with three popular variable selection methods: LASSO, SCAD, and MCP. Method. The three methods with the proposed screenings were applied to prostate cancer data with presence of metastasis as the outcome. Results. Simulations showed that the three variable selection methods with the proposed screenings controlled the predefined FDR and produced high area under the receiver operating characteristic curve (AUROC) scores. In applying these methods to the prostate cancer example, LASSO and MCP selected 12 and 8 genes and produced AUROC scores of 0.746 and 0.764, respectively. Conclusions. We demonstrated that the variable selection methods with the sequential use of FDR and ISIS not only controlled the predefined FDR in the final models but also had relatively high AUROC scores.
SubjectArea Under Curve
Data Interpretation, Statistical
False Positive Reactions
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Reproducibility of Results
Sensitivity and Specificity
Published Version (Please cite this version)10.1155/2016/8209453
Publication InfoKim, Sangjin; & Halabi, Susan (2016). High Dimensional Variable Selection with Error Control. Biomed Res Int, 2016. pp. 8209453. 10.1155/2016/8209453. Retrieved from https://hdl.handle.net/10161/15383.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor of Biostatistics and Bioinformatics
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.